UK markets closed

Fulcrum Therapeutics, Inc. (FULC)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
7.45-0.35 (-4.49%)
At close: 04:00PM EDT
7.45 0.00 (0.00%)
After hours: 07:39PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 463.04M
Enterprise value 259.87M
Trailing P/E 315.25
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)183.65
Price/book (mrq)2.17
Enterprise value/revenue 103.53
Enterprise value/EBITDA -10.84

Trading information

Stock price history

Beta (5Y monthly) 2.33
52-week change 3134.28%
S&P500 52-week change 323.76%
52-week high 313.70
52-week low 32.95
50-day moving average 37.66
200-day moving average 36.75

Share statistics

Avg vol (3-month) 3537.51k
Avg vol (10-day) 3562.84k
Shares outstanding 562.15M
Implied shares outstanding 662.15M
Float 843.8M
% held by insiders 11.38%
% held by institutions 197.78%
Shares short (15 May 2024) 43.09M
Short ratio (15 May 2024) 46.08
Short % of float (15 May 2024) 46.19%
Short % of shares outstanding (15 May 2024) 44.97%
Shares short (prior month 15 Apr 2024) 42.53M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-4,484.38%

Management effectiveness

Return on assets (ttm)-25.41%
Return on equity (ttm)-39.00%

Income statement

Revenue (ttm)2.51M
Revenue per share (ttm)0.04
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -110.47M
Net income avi to common (ttm)-99.43M
Diluted EPS (ttm)-1.61
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)213.31M
Total cash per share (mrq)3.43
Total debt (mrq)10.14M
Total debt/equity (mrq)4.75%
Current ratio (mrq)20.38
Book value per share (mrq)3.44

Cash flow statement

Operating cash flow (ttm)-92.13M
Levered free cash flow (ttm)-56.89M